All

Seventure Partners Life Sciences Investing Update – H2 2017
18 January 2018

Seventure Partners Life Sciences Investing Update – H2 2017

“2017 ended on a high note. Our Health For Life Capital™ investment vehicle has backed some truly remarkable disruptive technologies over the second half of the year and...

Read the press release
Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome
7 December 2017

Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome

VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has recieved Orphan Drug designation from the US FDA for C. difficile...

Read the press release
Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy
1 December 2017

Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy

New collaborations with Leiden University Medical Center and the Mitchell Cancer Institute focused on melanoma and cancers of the bladder, head and neck, and kidneys

Read more
Scipio bioscience announces its seed funding of €1.2m obtained from Seventure Partners’ Quadrivium I seed fund and High-Tech Gründerfonds
14 November 2017

Scipio bioscience announces its seed funding of €1.2m obtained from Seventure Partners’ Quadrivium I seed fund and High-Tech Gründerfonds

Scipio bioscience, a Paris-based biotechnology company devoted to providing a novel sample preparation solution for single-cell studies in the form of benchtop kits, announces...

Read the press release
Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers
30 October 2017

Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers

ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse